<DOC>
	<DOCNO>NCT01911754</DOCNO>
	<brief_summary>The purpose study obtain immunogenicity safety data H5N1 pandemic influenza vaccine Japanese pediatric population age 6 month 17 year</brief_summary>
	<brief_title>Japanese Pediatric H5N1 Vaccine Study</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant 6 month 17 year old time screening . Participant born full term pregnancy ( ≥37 week ) birth weight ≥2 kg ( participant age 6 35 month ) . Participant generally healthy , determine investigator 's clinical judgment collection medical history physical examination . If female childbearing potential , participant negative pregnancy test within 24 hour prior first schedule vaccination agree employ adequate birth control measure study duration . Participant and/or parents/legal guardian is/are willing able comply protocol requirement . Participant history exposure H5N1 virus history vaccination H5N1 influenza vaccine . Participant high risk contract H5N1 influenza infection ( e.g . contact poultry ) . Participant currently history significant cardiovascular ( include hypertension ) , respiratory ( include asthma ) , metabolic , neurological ( include GuillainBarré Syndrome acute disseminate encephalomyelitis ) , hepatic , rheumatic , autoimmune , hematological , gastrointestinal renal disorder . Participant inherit acquire immunodeficiency Participant disease currently undergoing form treatment undergoing form treatment within 30 day prior study entry expect influence immune response . Such treatment include , limited : systemic inhaled corticosteroid radiation treatment immunosuppressive cytotoxic drug . Participant history severe allergic reaction anaphylaxis . Participant rash , dermatological condition tattoo may interfere injection site reaction rating . Participant receive blood transfusion , immunoglobulins blood derivative within 90 day prior study entry . Participant donate blood plasma within 30 day prior study entry . Participant receive live vaccine within 4 week inactivate vaccine within 2 week prior vaccination study . Participant functional surgical asplenia . Participant know suspect problem alcohol drug abuse . Participant expose investigational product ( IP ) within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study . Participant family member employee investigator . Participant pregnant lactating time enrollment . Participant condition disqualifies his/her participation study opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>